The new MEDRAD XDS extravasation detector technology for the Stellant CT Injection System directly senses contrast or saline pooling under a patient’s skin during a Computed Tomography (CT) procedure. The patented XDS technology is designed to prevent moderate to severe extravasations that may seriously injure patients.
Reliable Radiofrequency Technology Makes the Difference
The MEDRAD XDS uses patented and safe radiofrequency (RF) wave technology to reliably detect an extravasation and stop the injection before the extravasation becomes severe.
Upon Activation, the XDS establishes a baseline measurement for the specific patient. During the injection, the XDS passes an RF signal through the injection site tissue to directly detect the presence of an extravasation. The signal passes freely through the tissue when there is no extravasated fluid. If an extravasation occurs, the signal change is detected and the injection is stopped.
Easy to use without interrupting workflow
• Exclusive RF wave technology enables the XDS to minimize false positive detections that interrupt workflow
• Set up is quick and easy
• XDS sterile disposables are designed to allow easy and consistent positioning of the XDS sensors
• MEDRAD’s exclusive HandiSTRIPS are like having a third hand to quickly and easily secure the catheter, tubing and XDS components
• Sterile HandiSTRIPS can replace non-sterile tape and eliminate the need to manually prepare strips of tape for each procedure
Enhanced patient safety at every step
1. The sensors of the XDS are placed on the patient where they will not interfere with palpation, a “critical step in preventing significant extravasation” according to the American College of Radiology’s Manual on Contrast Media1
2. HandiSTRIPS help you achieve compliance with current CDC recommendations for the proper insertion of Catheter-over –needles to reduce the risk of infection2
3. The XDS self-test feature verifies correct operation of the sensors prior to attaching the XDS to each patient, so you can be confident that the system is working properly
4. Upon Activation, the XDS establishes a baseline for each patient to optimize its ability to detect an extravasation
The XDS fully integrates with MEDRAD’s Stellant CT Injection System, which was developed with patient safety as a priority. Saline Test Inject allows you to confirm patency of the vein before delivering contrast. The Pressure Monitor Graph displays real-time pressure during injection, enabling the operator to quickly identify pressure issues, and reduce patient risk.
One serious extravasation is one too many
Although the frequency of serious extravasations is low, just one major event can put your patients at risk, subject your hospital and staff to liability costs, and potentially damage your hospital’s reputation3. By using the XDS on every patient, you are more likely to prevent a serious extravasation and the cost associated with it.
References:
1 ”Injection of Contrast Media” American College of Radiology. Accessed 5 October 2009.
http://www.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx
2 O’Grady NM, Alexander M, Dellinger E.P et al “Guidelines for the Prevention of Intravascular Catheter-Related Infections.” 9 August 2002. Center for Disease Control and Prevention. Accessed 5 October 2009. http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5110a1.htm
3 Paice, Timothy. “Economic Impact of an Extravasation: An Analysis.” May 2007. Imaging Economics. Accessed 5 October 2009.
http://www.imagingeconomics.com/issues/articles/2007-03_05.asp?mode=print